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provided the strongest evidence of an association with sexual dys-
function following antidepressant treatment. However, our results
are likely due to chance and there was no strong supporting evi-
dence in our replication cohort. The lack of biological plausibility
in the identified genes also reduces confidence in our findings. The
inclusion of an interaction term in our regression model allowed
us to identify genetic variants whose association with sexual
dysfunction differed by antidepressant (SSRI or NARI), which are
clinically important, but also increased our chances of obtaining
spurious associations. Larger, randomised controlled trials are
required before pharmacogenetics may be able to guide clinical
practice in reducing antidepressant-induced sexual dysfunction.
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Depressive disorders (DDs) are common psychiatric disorders
worldwide whose pathophysiology is linked to an alteration of
central monoaminergic systems. In particular, reduction of sero-
tonergic metabolism was evoked in depressed patients and most
current antidepressant drugs are selective serotonin/noradrenaline
reuptake inhibitors, such as fluoxetine. However the clinical ef-
ficacy of these drugs is restricted to a chronic administration,
about half of target patients remain partial or non-responders
and these compounds display substantial adverse side effects,
responsible for discontinuation of treatment. Accumulating evi-
dences have suggested that such psychiatric disorders are closely
associated with abnormalities in brain microtubule function. Since
last decade, we have developed various neurosteroids that target
the microtubular system. Accordingly, we have proposed that
neurosteroids, acting on the cytoskeleton, may constitute a new
original therapeutic approach for DDs. Hence, we found that the
3b-Methoxy-pregnenolone (MAP4343), a derivative compound of
pregnenolone, displays a very interesting and unique antidepres-
sant activity.
We investigated the antidepressant effects of MAP4343 in two
validated animal models of DDs consisting in (i) the Wistar Kyoto
(WKY) rats, a spontaneous model which is known to be resistant
to classic antidepressants, and (ii) the tree-shrews subjected to
psychosocial stress which is considered as a non-human primate
model. These animals received either acute (4 days in KWY rats)
or chronic (4 wks in three shrews) administration of MAP4343.
We assessed in KWY rats the ‘depressive-like’ behavior using
the forced-swimming (FST) test and the ‘anxious-like’ behavior
using the open-field. In tree-shrew, locomotor activity (LMA) and
avoidance behavior were videotaped, while various physiological
parameters known to be disturbed in DDs (sleep activity, core body
temperature and hormone secretion) were measured. Finally, ex-
pressions of a-tubulin isoforms (tyrosinated versus detyrosinated)
were measured in hippocampus from these two models, thereby
the infrared Western-blot technique, and the ratio tyrosinated
Tubulin/detyrosinated Tubulin (Tyr/Glu-Tub ratio) was taken as
index of microtubular dynamics.
When compared to vehicle-treated WKY rats, we found that
acute administration of MAP4343 (10mg/kg/day, s.c.) signifi-
cantly reduced the immobility in FST (−39%, p< 0.01, n = 8)
whereas fluoxetine displayed an inverse effect. MAP4343 was
able to increase the LMA in open-field arena (+56%, p< 0.001,
n = 8), while fluoxetine had no effect. In tree-shrews, chronic oral
administration of MAP4343 (50mg/Kg/day, per os) significantly
reversed stress-induced LMA reduction and stress-elicited avoid-
ance behavior. In addition, MAP4343 can prevent stress-induced
hypothermia, sleep disturbances and noradrenaline hypersecretion.
Finally, a reduced Tyr/Glu-Tub ratio was found in these two
models showing an alteration of microtubular dynamics in DDs.
However, this alteration was not prevented by MAP43, suggesting
that MAP43 does not directly act at the level of microtubular
assembly.
Taken together, these data display a robust and potent antide-
pressant effect of MAP4343 compound, evidenced under both
acute and chronic administration, in two validated models of
depression from two species. Relevant antidepressant effects were
demonstrated here on translational (both behavioral and phys-
iological) parameters, known to be disturbed in DDs. Further
investigations, using more accurate techniques, are in progress
to elucidate the cellular mechanism of action of MAP4343, in
particular on microtubular dynamics.
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MicroRNAs (miRNAs) are small non-coding RNAs (20−22 nu-
cleotides) which regulate protein synthesis post-transcriptionally
by base-pairing to target mRNAs. Generally, miRNAs inhibit
protein synthesis either by repressing translation or by inducing
deadenylation and degradation of target mRNAs, and they are
predicted to regulate more than 50% of all the protein-coding
genes. It has been reported that almost 50% of all the so
far identified miRNAs are expressed in the human brain, with
putative target genes regulating synaptogenesis and other basic
neuronal processes. A role for miRNAs in neurogenesis, neuronal
differentiation and survival, as well as in neuroplasticity, is now
well established. Moreover, recent studies suggest that miRNAs
may be involved in the pathophysiology of neuropsychiatric dis-
orders and in the action of psychotropic drugs [1]. Alterations in
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miRNA expression have been observed, among others, in major
depression (MD) and bipolar disorder (BD), and their modulation
has been described after treatments with antidepressant [3] and
mood stabilizer drugs. In particular, intriguing findings concern
the identification of disease- and treatment-associated miRNA
signatures in patients’ peripheral tissues, such as blood; this may
provide further insights into the etiopathogenesis of MD and
BD and contribute to identify new biomarkers for diagnostic
assessment improvement and treatment personalization.
Thus, the aim of this study was to investigate miRNA ex-
pression levels in the blood of 20 MD and 20 BD patients,
compared to 20 healthy controls. All the patients were in a
depressive state [Hamilton Depression Rating Scale (HAMD)
score 15] and drug-free from antidepressants; BD patients
were in treatment with mood stabilizers. Total RNA was ex-
tracted from 2.5mL of peripheral blood with the PAXGene
Blood miRNA Kit (Qiagen) and analyzed with the GeneChip
miRNA 3.0 Arrays (Affymetrix), which cover all the 1733 ma-
ture miRNAs and 1658 pre-miRNAs annotated in miRBase (on-
line miRNA database, http://www.mirbase.org) version 17 (April
2011). Data were then analyzed with Partek Genomics Suite
software, and the most significant results were confirmed by
real-time PCR using the TaqMan MicroRNA Assays (Applied
Biosystems). Five miRNAs were detected as differentially ex-
pressed only in MD patients, 5 only in BD patients, while
3 miRNAs were commonly modulated in MD and BD pa-
tients. A pathway analysis, which works by identifying the tar-
get genes of selected miRNAs, was performed with the on-
line tool DIANA-miRPath (http://diana.imis.athena-innovation.gr/
DianaTools/index.php?r=mirpath/index) and revealed the presence
of common altered pathways in MD and BD, such as long-
term potentiation and depression, axon guidance, ErbB, TGF-beta,
mTOR, Wnt, PI3K-Akt and neurotrophin signaling pathways,
and the specific involvement of dopaminergic and glutamatergic
synapse pathways for BD.
These results highlight a dysregulation in the expression of
specific blood miRNAs in patients suffering from mood disorders
and suggest putative specific alterations in the regulation of
genes related to the dopaminergic and glutamatergic systems in
BD patients.
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Epigenetic mechanisms mediate stable functional changes in brain
plasticity in response to environmental stimuli. Among them,
stress-mediated changes in histone acetylation, regulated by the
superfamily of histone deacetylases (HDAC’s), could contribute to
the pathogenesis of depression. Likewise, antidepressant therapy
might counteract these effects [1,2].
Emerging clinical interest in the mechanisms that link exposure
to stressful situations to the perpetuation of depressive disorders
and/or increased vulnerability to relapse has stimulated the study
of mouse specific models from a longitudinal perspective, aiming
to identify stable neuroadaptations induced by stress. The chronic
social defeat stress (CSDS) model has its theoretical rationale in
the induction of ‘social subordination’ caused by short periods of
struggle with a dominant animal followed by fellowship in an ady-
acent cage. CSDS induces long-lasting anhedonia, a core symptom
of clinical depression, but also anxiety and social avoidance.
Interestingly, some of these behaviours are effectively reversed
or prevented by different monoaminergic antidepressants [3].
We hypothesise that the long-term behavioural deficits induced
by CSDS could be related to neuroadaptive changes in areas
such as the prefrontal cortex, which, is compromised in depressed
patients. Using the chronic social defeat stress (CSDS) model of
depression we aimed to study the HDAC’s regulation by stress
and imipramine treatment in the prefrontal cortex (PFC), their
functional implications and relevance to depression.
Methods: Mice were exposed to CSDS (10 days) followed
by saline or imipramine (10mg/kg/day, 4 weeks). The PFC was
obtained 24 h after the last drug administration and hdac’s mRNA
was studied and compared to human studies using the TaqMan
Low Density Arrays (TLDA) microfluidic card technology. The
protein expression of selected HDAC’s, histone acetylation and
other synaptic plasticity markers was explored by western-blot.
Further, the effect of repeated treatment with specific HDAC’s
inhibitors in histone acetylation and the expression of synaptic
plasticity markers were also explored.
Results: While CSDS increased hdac5 and sirt2 mRNA,
repeated imipramine downregulated mRNA of these enzymes.
However, HDAC5 protein and its phosphorylated cytoplasmic
form (p-HDAC5) were strikingly upregulated by imipramine.
Sirt2 protein was oppositely regulated by stress and imipramine.
Moreover, imipramine-induced Sirt2 inhibition correlated with
increased acetylated a-tubulin, the Sirt2 cytoplasmic sub-
strate. Subsequently, while CSDS decreased acetylated his-
tone 3 and CREB levels, imipramine induced an increase of
both acetylated histone 3 and 4 as well as pro-BDNF and
CREB.
Further, both the class II HDAC inhibitor MC1568 (25mg/kg, 3
weeks) and the sirt2 inhibitor 33i (1mg/kg, three weeks) elevated
acetylation levels of histone 4 and increased expression of pro-
BDNF and CREB.
Conclusion: Our results suggest a role for HDAC5 and Sirt2
in stress-induced neuronal adaptations and in the mechanism of
action of imipramine treatment, by which, it might stimulate the
expression of specific genes involved in synaptic plasticity.
